| Literature DB >> 24348841 |
Chuan Xie1, Li-Yao Xu1, Zhen Yang1, Xi-Mei Cao1, Wei Li1, Nong-Hua Lu1.
Abstract
Phosphorylation of H2AX at Ser 139 (γH2AX) is a biomarker of DNA double-strand breaks (DSBs). The present study aimed to explore the association between γH2AX levels and gastric pathology and Helicobacter pylori (H. pylori) infection. Gastric biopsies were obtained from 302 H. pylori-negative and -positive patients, including those with chronic gastritis (CG), intestinal metaplasia (IM), dysplasia (Dys) and gastric cancer (GC). Proteins were extracted from five gastric epithelial cell lines and from 10 specimens of matched GC and adjacent normal tissues. The expression of γH2AX, a biomarker for the detection of DNA DSBs, in gastric tissues was detected by immunohistochemistry and western blotting. The expression of γH2AX progressively increased in tissues according to pathological stage from CG to Dys, but was slightly decreased in GC. H. pylori infection was associated with increased γH2AX expression, IM and Dys. Overexpression of γH2AX in GC was found to correlate with tumor location, gross appearance, differentiation, depth of invasion, TNM stage and lymph node metastasis. The results indicated that DSBs appear to be an early molecular event in gastric carcinogenesis, which may be associated with H. pylori infection. Moreover, immunohistochemical staining of γH2AX was found to correlate with a number of clinicopathological characteristics. The expression of γH2AX may serve as a valuable biomarker for the diagnosis and progression of GC.Entities:
Keywords: DNA double-strand breaks; Helicobacter pylori; gastric carcinogenesis; γH2AX
Year: 2013 PMID: 24348841 PMCID: PMC3861580 DOI: 10.3892/ol.2013.1693
Source DB: PubMed Journal: Oncol Lett ISSN: 1792-1074 Impact factor: 2.967
Expression of γH2AX in patients with various histological observations.
| Overall score of | |||||||||
|---|---|---|---|---|---|---|---|---|---|
|
| |||||||||
| Group | n | Mean age (SD), years | Gender, M/F | −, n | +, n | ++, n | +++, n | % | P-value |
| 1 CG | 56 | 53.6 (10.7) | 30/26 | 29 | 27 | 0 | 0 | 48.2 | |
| 2 IM | 53 | 54.3 (9.6) | 29/24 | 14 | 26 | 12 | 1 | 73.5 | <0.001 |
| 3 Dys | 47 | 55.1 (10.3) | 26/21 | 2 | 9 | 27 | 9 | 95.7 | <0.001 |
| 4 GC | 146 | 56.8 (14.1) | 96/50 | 15 | 57 | 50 | 24 | 89.7 | <0.001 |
Percentage of immunostaining.
vs. CG group;
vs. IM group;
vs. Dys group.
γH2AX, phosphorylated H2AX at Ser 139; M, male; F, female; CG, chronic gastritis; IM, intestinal metaplasia; Dys, dysplasia; GC, gastric cancer.
Figure 1Immunohistochemical staining of γH2AX protein in (A) chronic gastritis, (B) intestinal metaplasia, (C) dysplasia and (D) gastric carcinoma tissues (magnification, ×200; scale bar, 40 μm). γH2AX, phosphorylated H2AX at Ser 139.
Figure 2Relative γH2AX protein expression levels in gastric carcinoma compared with adjacent non-tumorous mucosa. Immunoblots of γH2AX were scanned and the relative protein expression level of tumor samples were compared with their adjacent non-cancerous counterparts and expressed as a percentage of β-actin. *P<0.001. γH2AX, phosphorylated H2AX at Ser 139.
Expression of γH2AX in patients with various histological observations, in relation to H. pylori infection.
| Overall score of | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
| ||||||||||
| Group | n | Mean age (SD), years | Gender, M/F | −, n | +, n | ++, n | +++, n | % | P-value | |
| CG | + | 26 | 54.1 (11.7) | 14/12 | 7 | 19 | 0 | 0 | 73.1 | 0.362 |
| − | 30 | 53.2 (9.1) | 16/14 | 22 | 8 | 0 | 0 | 26.7 | ||
| IM | + | 29 | 54.8 (8.8) | 14/15 | 1 | 19 | 8 | 1 | 96.5 | 0.001 |
| − | 24 | 53.7 (10.3) | 15/9 | 13 | 7 | 4 | 0 | 45.8 | ||
| Dys | + | 26 | 54.3 (12.2) | 13/13 | 0 | 2 | 17 | 7 | 100.0 | 0.008 |
| − | 21 | 56.1 (9.5) | 13/8 | 2 | 7 | 10 | 2 | 90.4 | ||
| GC | + | 61 | 58.3 (16.3) | 39/22 | 6 | 25 | 20 | 10 | 90.2 | 0.865 |
| − | 85 | 50.8 (13.9) | 57/28 | 9 | 32 | 30 | 14 | 89.4 | ||
Percentage of immunostaining.
γH2AX, phosphorylated H2AX at Ser 139; H. pylori: Helicobacter pylori; M, male; F, female; CG, chronic gastritis; IM, intestinal metaplasia; Dys, dysplasia; GC, gastric cancer.
Clinicopathological association of γH2AX expression in patients with GC.
| Overall score of | |||||||
|---|---|---|---|---|---|---|---|
|
| |||||||
| Characteristics | n | −, n | +, n | ++, n | +++, n | PR, % | P-value |
| Gender | |||||||
| Male | 96 | 8 | 39 | 35 | 14 | 91.7 | 0.923 |
| Female | 50 | 7 | 18 | 15 | 10 | 86.0 | |
| Age, years | |||||||
| ≥55 | 86 | 7 | 36 | 28 | 15 | 91.8 | 0.780 |
| <55 | 60 | 8 | 21 | 22 | 9 | 86.7 | |
| Location | |||||||
| Antrum | 74 | 13 | 31 | 25 | 5 | 82.4 | <0.001 |
| Body and cardia | 72 | 2 | 26 | 25 | 19 | 97.2 | |
| Gross type (Borrmann) | |||||||
| I and II | 72 | 8 | 37 | 21 | 6 | 88.9 | 0.002 |
| III and IV | 74 | 7 | 20 | 29 | 18 | 90.5 | |
| Differentiation | |||||||
| Well and moderately | 81 | 11 | 40 | 21 | 9 | 74.1 | |
| Poorly and undifferentiated | 65 | 4 | 17 | 29 | 15 | 93.8 | <0.001 |
| Invasive depth | |||||||
| Above submucosa | 27 | 4 | 18 | 3 | 2 | 85.1 | |
| Muscularis propria | 8 | 2 | 0 | 3 | 3 | 75.0 | 0.080 |
| Below subserosa | 111 | 9 | 39 | 44 | 19 | 91.9 | 0.002 |
| TNM | |||||||
| I and II | 59 | 8 | 35 | 12 | 3 | 86.4 | <0.001 |
| III and IV | 87 | 7 | 22 | 38 | 20 | 91.9 | |
| Lymph node metastasis | |||||||
| With | 113 | 10 | 37 | 45 | 21 | 91.2 | 0.002 |
| Without | 33 | 5 | 20 | 5 | 3 | 84.8 | |
vs. above submucosa;
vs. muscularis propria.
γH2AX, phosphorylated H2AX at Ser 139; GC, gastric cancer; PR, positive rate.
Figure 3Expression of γH2AX in non-cancerous and cancerous gastric cell lines measured by western blotting. Cell lines were grown for two days and then subjected to total cellular protein isolation. γH2AX, phosphorylated H2AX at Ser 139.